## BIOVECBLOK S.r.I.

NATURAL SOLUTIONS AGAINST MOSQUITOES





#### TEAM - Co-founder







R&D Manager




relazioni internazionali ed acquisizione fondi

VEDI PROFILO
























































### GLOBALSOCIALVENTURE

COMPETITION









### GLOBALSOCIALVENTURE

COMPETITION



THE FUTURE OF SOCIAL VENTURES

UNIVERSITY OF CALIFORNIA, BERKELEY

APRIL 6-7, 2017





### **GLOBALSOCIALVENTURE**



he Future of Social Ventures Confer " Annual Global Social Venture Com SUTURE OF SOCIAL LEAVING GLOBAL SOCIAL THE . ATLAS S. same Ton Thousand Unly BorkeleyHaas state of the state



Scienza

Tecnologia

Creatività

Social Innovation

Dossier

Blog



### CORRIERE DELLA SERA



24 aprile 2017

# La Startup italiana che sbanca negli States con l'insetticida bio contro malaria, dengue e zika

di Gaia Pascucci



Accueil > Politique étrangère de la France > Diplomatie scientifique > Veille scientifique et technologique > Italie

A+ A- 3

### Atlas: Un insecticide biologique conçu par la startup italienne BIOVECBLOK à l'honneur de la Global Social Venture Competition






### 2018 - BRASILE



### BIOVECBLOK BRAZIL





## The Washington Post

Brazil's government has authorized hundreds of millions of dollars to slow the spread of transmissible diseases such as Zika — with \$230 million made available to states in the past two years alone.









#### **BBC** BRASIL

#### OMS vê risco de intensificação do surto de febre amarela





G

MINAS GERAIS ...



#### Governo de Minas confirma 38 mortes por febre amarela

Casos confirmados da doença pela secretaria de saúde são 67. Minas passa pelo pior surto de febre amarela já registrado.










## 2018 - BRASILE





# 2018 - BRASILE





## 2018 - CROWDFUNDING





Scienza

Tecnologia

Creatività

Social Innovation

Dossie

Blog





www.nextequity.it

"What we do for ourselves dies with us. What we do for others and the world remains and is immortal."

Albert Pike

